[1] Global tuberculosis report 2019. Geneva: World Health Organization; 2019.
[2] Garrido-Cardenas JA, de Lamo-Sevilla C, Cabezas-Fernández MT, Manzano-Agugliaro F, Martínez-Lirola M. Global tuberculosis research and its future prospects. Tuberculosis 2020;121:101917.
[3] Sushruta H, Prasad SV, Santosh G, et al. Antimycobacterial susceptibility evaluation of rifampicin and isoniazid benz-hydrazone in biodegradable polymeric nanoparticles against Mycobacterium tuberculosis H37Rv strain. International Journal of Nanomedicine 2018;13:4303-18.
[4] Hockhausen K, Odegaard K, Boersma B, Keegan JM. A Review of Extrapulmonary Tuberculosis. 2018;71:116-19.
[5] Sotgiu G, Sulis G, Matteelli A. Tuberculosis-a World Health Organization Perspective. Microbiology Spectrum 2017;5.
[6] Toit LCD, Pillay V, Danckwerts MP. Tuberculosis chemotherapy: current drug delivery approaches. Respiratory Research 2006;7:118.
[7] Ariel PM, Gowda DK, Frieden TR. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework. Bull World Health Organ 2002;80:489-95.
[8] Ahuja SD, David A, Monika A, Rita B, Melissa B, Bayona JN, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Medicine 2012; 9: e1001300.
[9] Kalhapure RS, Nadia S, Chunderika M, Nasreen S, Thirumala G. Nanoengineered drug delivery systems for enhancing antibiotic therapy. Journal of Pharmaceutical Sciences 2015;104:872-905.
[10] Huh AJ, Kwon YJ. "Nanoantibiotics": a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era. Journal of Controlled Release 2011;156:128-45.
[11] Shegokar R, Al SL, Mitri K. Present status of nanoparticle research for treatment of tuberculosis. Journal of Pharmacy & Pharmaceutical Sciences 2011;14:100-16.
[12] Bansal R, Sharma D, Singh R. Tuberculosis and its Treatment: An Overview. Mini-Reviews in Medicinal Chemistry 2017;18:58-71.
[13] Gashu KD, Gelaye KA, Mekonnen ZA, Lester R, Tilahun B. Does phone messaging improves tuberculosis treatment success? A systematic review and meta-analysis. BMC infectious diseases 2020;20:42.
[14] Abdelhamid HN, Wu HF. Proteomics analysis of the mode of antibacterial action of nanoparticles and their interactions with proteins. Trac Trends in Analytical Chemistry 2015;65:30-46.
[15] Abed N, Couvreur P. Nanocarriers for antibiotics: a promising solution to treat intracellular bacterial infections. Int J Antimicrob Agents 2014;43:485-96.
[16] Cheow WS, Hadinoto K. Antibiotic Polymeric Nanoparticles for Biofilm-Associated Infection Therapy. Methods in Molecular Biology 2014;1147:227-38.
[17] Gao W, Chen Y, Zhang Y, Zhang Q, Zhang L. Nanoparticle-based local antimicrobial drug delivery. Advanced Drug Delivery Reviews 2018;127:46-57.
[18] Chereddy KK, Vandermeulen G, Préat V. PLGA based drug delivery systems: Promising carriers for wound healing activity. Wound Repair & Regeneration 2016;24:223-36.
[19] Lavon I, Kost J. Ultrasound and transdermal drug delivery. Drug Discovery Today 2004;9:670-6.
[20] Hideo U, Mizue M, Toshinobu S, Daisuke K, Yasunori M. Acoustic cavitation as an enhancing mechanism of low-frequency sonophoresis for transdermal drug delivery. Biological & Pharmaceutical Bulletin 2009;32:916-20.
[21] Sassaroli E, Hynynen K. Cavitation Threshold of Microbubbles in Gel Tunnels by Focused Ultrasound. Ultrasound in Medicine & Biology 2007;33:1651-60.
[22] Miller D, Dou C. Induction of apoptosis in sonoporation and ultrasonic gene transfer. Ultrasound in Medicine & Biology 2009;35:144-54.
[23] Yu H, Chen S, Cao P. Synergistic bactericidal effects and mechanisms of low intensity ultrasound and antibiotics against bacteria: a review. Ultrasonics - Sonochemistry 2012;19:377-82.
[24] Yu-Ying, Fu, Liang, Zhang, Yi, Yang, et al. Synergistic antibacterial effect of ultrasound microbubbles combined with chitosan-modified polymyxin B-loaded liposomes on biofilm-producing Acinetobacter baumannii. International Journal of Nanomedicine 2019; 14:1805–15.
[25] Wang X, Ip M, Leung AW, Yang Z, Wang P, Zhang B, et al. Sonodynamic action of curcumin on foodborne bacteria Bacillus cereus and Escherichia coli. Ultrasonics 2015; 62:75-9.
[26] Dong Y, Su H, Jiang H, Zheng H, Du Y, Wu J, et al. Experimental study on the influence of low-frequency and low-intensity ultrasound on the permeability of the Mycobacterium smegmatis cytoderm and potentiation with levofloxacin. Ultrasonics Sonochemistry 2017;37:1-8.
[27] Yang M, Xie S, Adhikari VP, Dong Y, Du Y, Li D. The Synergistic Fungicidal Effect of Low-Frequency and Low-Intensity Ultrasound with Amphotericin B-loaded Nanoparticles on C. albicans in Vitro. International Journal of Pharmaceutics 2018;542:232-41.
[28] Yang M, Du K, Hou Y, Xie S, Dong Y, Li D, et al. Synergistic Antifungal Effect of Amphotericin B-Loaded Poly(Lactic-Co-Glycolic Acid) Nanoparticles and Ultrasound against Candida albicans Biofilms. Antimicrobial agents and chemotherapy 2019;63. e02022-18.
[29] Reyrat JM, Kahn D. Mycobacterium smegmatis: an absurd model for tuberculosis? Trends in Microbiology 2001;9:472-4.
[30] García MdlA, Borrero R, Lanio ME, Tirado Y, Acosta A. Protective Effect of a Lipid-Based Preparation from Mycobacterium smegmatis in a Murine Model of Progressive Pulmonary Tuberculosis. Journal of Biomedicine and Biotechnology 2014.
[31] Tirado Y, Puig A, Alvarez N, Borrero R, Aguilar A, Camacho F, et al. Mycobacterium smegmatis proteoliposome induce protection in a murine progressive pulmonary tuberculosis model. Tuberculosis 2016;101:44-8.
[32] Altaf M, Miller CH, Bellows DS, O’Toole R. Evaluation of the Mycobacterium smegmatis and BCG models for the discovery of Mycobacterium tuberculosis inhibitors. Tuberculosis 2010;90:333-7.
[33] Edagwa BJ, Guo D, Puligujja P, Chen H, Mcmillan JE, Liu X, et al. Long-acting antituberculous therapeutic nanoparticles target macrophage endosomes. Faseb Journal 2014;28:5071-82.
[34] Balaraman, Kalyanaraman, and, Victor, Darley-Usmar, and, et al. Measuring reactive oxygen and nitrogen species with fluorescent probes: challenges and limitations. Free Radical Biology & Medicine 2012;52:1-6.
[35] Barner A, Myers M. The effects of carboxylic acids on the aqueous dispersion and electrophoretic deposition of ZrO2. Journal of the European Ceramic Society 2013;32:235-44.
[36] Pieters J. Mycobacterium tuberculosis and the Macrophage: Maintaining a Balance. Cell Host & Microbe 2008;3:399-407.
[37] Georgy M, Ursa M, Magaeva AA, Itin VI, Naiden EP, Ivan P, et al. Ferri-liposomes as an MRI-visible drug-delivery system for targeting tumours and their microenvironment. Nature Nanotechnology 2011;6:594-602.
[38] Georgy M, Ursa M, Magaeva AA, Itin VI, Naiden EP, Ivan P, et al. Ferri-liposomes as an MRI-visible drug-delivery system for targeting tumours and their microenvironment. Nature Nanotechnology 2011;6:594-602.
[39] Jain A, Tiwari A, Verma A, Jain SK. Ultrasound-based triggered drug delivery to tumors. Drug Delivery & Translational Research 2018;8:150-64.
[40] Yu T, Enguo J, Jinsong R, Xiaogang Q. Bifunctionalized mesoporous silica-supported gold nanoparticles: intrinsic oxidase and peroxidase catalytic activities for antibacterial applications. Advanced Materials 2015;27:1097-104.
[41] Dong M, Green AM, Willsey GG, Marshall JS, Wargo MJ, Junru W. Effects of acoustic streaming from moderate-intensity pulsed ultrasound for enhancing biofilm mitigation effectiveness of drug-loaded liposomes. Journal of the Acoustical Society of America 2015;138:1043-51.
[42] Shen S, Wu L, Xie M, Shen H, Qi X, Yan Y, et al. Core–shell structured Fe 3 O 4 @TiO 2 -doxorubicin nanoparticles for targeted chemo-sonodynamic therapy of cancer. Int J Pharm 2015;486:380-8.
[43] Wang H, Li M, Hu J, Wang C, Xu S, Han CC. Multiple Targeted Drugs Carrying Biodegradable Membrane Barrier: Anti-Adhesion, Hemostasis, and Anti-Infection. Biomacromolecules 2013;14:954-61.
[44] Zhao Z, Yan R, Yi X, Li J, Chen C. Bacteria-Activated Theranostic Nanoprobes against Methicillin-Resistant Staphylococcus aureus Infection. ACS nano 2017;11:4488-38.
[45] Yang C, Ren C, Zhou J, Liu J, Zhang Y, Huang F, et al. Dual Fluorescent- and Isotopic-Labelled Self-Assembling Vancomycin for in?vivo Imaging of Bacterial Infections. Angewandte Chemie 2017;129:2396-400.
[46] Schroeder A, Avnir Y, Weisman S, Najajreh Y, Gabizon A, Talmon Y, et al. Controlling Liposomal Drug Release with Low Frequency Ultrasound: Mechanism and Feasibility. Langmuir the Acs Journal of Surfaces & Colloids 2007;23:4019-25.
[47] Ward M, Wu J, Chiu J. Experimental study of the effects of Optison concentration on sonoporation in vitro. Ultrasound in Medicine & Biology 2000;26:1169-75.
[48] Lammertink B, Deckers R, Storm G, Moonen C, Bos C. Duration of ultrasound-mediated enhanced plasma membrane permeability. International Journal of Pharmaceutics 2015;482:92-8.
[49] Yudina A, Lepetit-Coiffé M, Moonen CTW. Evaluation of the Temporal Window for Drug Delivery Following Ultrasound-Mediated Membrane Permeability Enhancement. Molecular Imaging & Biology Mib the Official Publication of the Academy of Molecular Imaging 2011;13:239-49.
[50] Mitragotri S, Kost J. Low-Frequency Sonophoresis: A Noninvasive Method of Drug Delivery and Diagnostics. Biotechnol Prog 2010;16:488-92.
[51] Su H, Li Z, Dong Y, Jiang HX, Zheng HM, Du YH, et al. Damage Effects on Bacille Calmette-Guérin by Low-Frequency, Low-Intensity Ultrasound: A Pilot Study. Journal of Ultrasound in Medicine Official Journal of the American Institute of Ultrasound in Medicine 2016;35:581–7.
[52] Paris JL, Mannaris C, Cabañas MV, Carlisle R, Manzano M, Vallet-Regí M, et al. Ultrasound-mediated cavitation-enhanced extravasation of mesoporous silica nanoparticles for controlled-release drug delivery. Chemical Engineering Journal 2018;340:2-8.
[53] Stuart I, Schutt, Esener. Microbubble-mediated ultrasound therapy: a review of its potential in cancer treatment. Drug Design Development & Therapy 2013;7:375-88.
[54] Chen M, Gan H, Remold HG. A Mechanism of Virulence: Virulent Mycobacterium tuberculosis Strain H37Rv, but Not Attenuated H37Ra, Causes Significant Mitochondrial Inner Membrane Disruption in Macrophages Leading to Necrosis. Journal of Immunology 2006;176:3707-16.
[55] Molloy A, Laochumroonvorapong P, Kaplan G. Apoptosis, but not necrosis, of infected monocytes is coupled with killing of intracellular bacillus Calmette-Guérin. Journal of Experimental Medicine 1994;180:1499-509.
[56] Dallenga T, Repnik U, Corleis Br, Eich J, Reimer R, Griffiths GW, et al. M.?tuberculosis -Induced Necrosis of Infected Neutrophils Promotes Bacterial Growth Following Phagocytosis by Macrophages. Cell Host & Microbe 2017;22:519-30.
[57] Behar SM, Martin CJ, Booty MG, Nishimura T, Zhao X, Gan H-X, et al. Apoptosis is an innate defense function of macrophages against Mycobacterium tuberculosis. Mucosal Immunology 2011;4:279-87.
[58] Pang X, Xiao Q, Cheng Y, Ren E, Lian L, Zhang Y, et al. Bacteria-Responsive Nanoliposomes as Smart Sonotheranostics for Multidrug Resistant Bacterial Infections. ACS nano 2019;13:2427-38.